Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for Severe COVID-19 Pneumonia in Japan
jRCT2080225174Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in coronavirus pneumonia and coronavirus disease 2019 (COVID-19), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Primary efficacy outcomes. Started Apr 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2080225174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225174.